These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6437113)

  • 21. A comparison of desferrioxamine-induced sideruria and measurement of labile iron store as indices of body iron status.
    Singh AK
    J Med; 1971; 2(6):345-62. PubMed ID: 5292126
    [No Abstract]   [Full Text] [Related]  

  • 22. Iron chelation.
    Hershko C; Pinson A; Link G
    Blood Rev; 1990 Mar; 4(1):1-8. PubMed ID: 2182144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemochromatosis and vitamin C.
    Herbert V
    Ann Intern Med; 1999 Sep; 131(6):475-6. PubMed ID: 10498572
    [No Abstract]   [Full Text] [Related]  

  • 24. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The inhibitory effect of vitamin E on desferrioxamine-induced iron excretion in rats.
    Hershko C; Rachmilewitz EA
    Proc Soc Exp Biol Med; 1976 Jun; 152(2):249-52. PubMed ID: 935189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Contribution to the problem of hemochromatosis].
    Bruns W; Michaelis D; Takác A; Langsch HG
    Dtsch Z Verdau Stoffwechselkr; 1966 Feb; 25(6):363-70. PubMed ID: 5998360
    [No Abstract]   [Full Text] [Related]  

  • 28. Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone.
    Christoforidis A; Zevgaridou E; Tsatra I; Perifanis V; Vlachaki E; Papassotiriou I; Apostolakou F; Athanassiou-Metaxa M
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):598-601. PubMed ID: 17805032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simple assay for urinary iron after desferrioxamine therapy.
    Pippard MJ; Stray S
    Am J Clin Pathol; 1982 Mar; 77(3):324-7. PubMed ID: 7072635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The diagnostic value of the desferrioxamine B test in the latent form of primary idiopathic hemochromatosis].
    Michaelis D; Takác A; Bruns W
    Acta Biol Med Ger; 1966; 16(3):300-8. PubMed ID: 4964937
    [No Abstract]   [Full Text] [Related]  

  • 31. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G
    Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug.
    Graziano JH; Grady RW; Cerami A
    J Pharmacol Exp Ther; 1974 Sep; 190(3):570-5. PubMed ID: 4416298
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of ascorbic acid on desferrioxamine-induced siderinuria].
    Bosello O; Mengoli C; Rossi G
    Fracastoro; 1971; 64(5):310-9. PubMed ID: 5151104
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effect of the ion-exchange resin desferrioxamine B on iron metabolism].
    Keler-Bacoka M; Hahn A
    Lijec Vjesn; 1965 Dec; 87(12):1329-38. PubMed ID: 5880072
    [No Abstract]   [Full Text] [Related]  

  • 36. Concomitant primary hemochromatosis and beta-thalassemia trait: iron depletion by erythrocytapheresis and desferrioxamine.
    Cesana M; Mandelli C; Tiribelli C; Bianchi PA; Conte D
    Am J Gastroenterol; 1989 Feb; 84(2):150-2. PubMed ID: 2916524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased urinary excretion of 8-iso-prostaglandin F2alpha in patients with HFE-related hemochromatosis: a case-control study.
    Kom GD; Schwedhelm E; Nielsen P; Böger RH
    Free Radic Biol Med; 2006 Apr; 40(7):1194-200. PubMed ID: 16545687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Desferrioxamine in patients with hemochromatosis and hemosiderosis].
    Maspes V; Tamigaki M; Gomes ZJ; Jamra M
    Rev Hosp Clin Fac Med Sao Paulo; 1966; 21(4):181-95. PubMed ID: 5918167
    [No Abstract]   [Full Text] [Related]  

  • 39. [Use of desferrioxamine B in normal subjects and in patients with increased iron storage].
    Muranda M; Velasco M; Giménez E; Ruiz J; Bastías E; Rodriguez J; Etcheverry R; Guzmán C; Regonesi C; Janklevich S
    Rev Med Chil; 1965 Apr; 93(4):127-33. PubMed ID: 5832943
    [No Abstract]   [Full Text] [Related]  

  • 40. Iron-chelating therapy.
    Hershko C; Weatherall DJ
    Crit Rev Clin Lab Sci; 1988; 26(4):303-45. PubMed ID: 3077034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.